Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response

Abstract : Non-Hodgkin lymphoma (NHL) is one of the most common malignancies and a major cause of morbidityand mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL which offers the combineduse of monoclonal antibodies for specific targeting of malignant cells and radiation for killing these cells.Despite the promising results favoring RIT in several clinical studies in different target populations andNHL types, Food and Drug Administration (FDA) approval for RIT agents is restricted to a limited numberof indications and agents, maybe because of several ambiguities that still exist in the field. One of theseambiguities are the lack of evidence-based prognostic factors that determine what patient populationwould benefit most from RIT, which is essential to know in order to optimize the efficacy and safetyof treatment with RIT. As well as selecting the best patient population for RIT, it is important to assessthe response to RIT in order to provide further treatment strategies or avoid unnecessary therapies anddiagnostic procedures. In this review we have explored the details of how to predict the efficiency of RIT∗
Type de document :
Article dans une revue
Critical Reviews in Oncology/Hematology, Elsevier, 2016, 107, pp.182 - 189. 〈10.1016/j.critrevonc.2016.10.005〉
Liste complète des métadonnées

Littérature citée [79 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01414377
Contributeur : Elizabeth Bernardo <>
Soumis le : lundi 12 décembre 2016 - 11:47:02
Dernière modification le : jeudi 20 septembre 2018 - 17:02:01
Document(s) archivé(s) le : lundi 27 mars 2017 - 16:21:06

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Mahsa Eskian, Mirhojjat Khorasanizadeh, Francoise Kraeber-Bodere, Nima Rezaei. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology, Elsevier, 2016, 107, pp.182 - 189. 〈10.1016/j.critrevonc.2016.10.005〉. 〈inserm-01414377〉

Partager

Métriques

Consultations de la notice

62